PT3844147T - Compostos - Google Patents
CompostosInfo
- Publication number
- PT3844147T PT3844147T PT208163766T PT20816376T PT3844147T PT 3844147 T PT3844147 T PT 3844147T PT 208163766 T PT208163766 T PT 208163766T PT 20816376 T PT20816376 T PT 20816376T PT 3844147 T PT3844147 T PT 3844147T
- Authority
- PT
- Portugal
- Prior art keywords
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1916210.6A GB201916210D0 (en) | 2019-11-07 | 2019-11-07 | High purity tryptamines and methods of synthesis thereof |
GBGB1917320.2A GB201917320D0 (en) | 2019-11-28 | 2019-11-28 | Novel compounds |
GB2008303.6A GB2585978B (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3844147T true PT3844147T (pt) | 2022-07-04 |
Family
ID=75849570
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT208163758T PT3873883T (pt) | 2019-11-07 | 2020-11-09 | Método de síntese |
PT208163766T PT3844147T (pt) | 2019-11-07 | 2020-11-09 | Compostos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT208163758T PT3873883T (pt) | 2019-11-07 | 2020-11-09 | Método de síntese |
Country Status (18)
Country | Link |
---|---|
US (4) | US11643390B2 (pt) |
EP (3) | EP3873883B1 (pt) |
JP (3) | JP7422473B2 (pt) |
KR (2) | KR20230142817A (pt) |
CN (2) | CN114829341B (pt) |
AU (2) | AU2020378647B2 (pt) |
BR (1) | BR112022008919A2 (pt) |
CA (2) | CA3160334C (pt) |
DK (1) | DK3844147T3 (pt) |
ES (2) | ES2940811T3 (pt) |
HR (2) | HRP20230281T1 (pt) |
HU (2) | HUE061482T2 (pt) |
IL (2) | IL292753B2 (pt) |
MX (1) | MX2022005399A (pt) |
NZ (1) | NZ788543A (pt) |
PL (2) | PL3844147T3 (pt) |
PT (2) | PT3873883T (pt) |
WO (2) | WO2021089872A1 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
PL3844147T3 (pl) | 2019-11-07 | 2022-07-18 | Small Pharma Ltd | Związki chemiczne |
CA3166936A1 (en) | 2020-02-04 | 2021-08-12 | Abdelmalik Slassi | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
US11332441B2 (en) * | 2020-03-23 | 2022-05-17 | Caamtech, Inc. | Crystalline N-methyl tryptamine derivatives |
US20230219889A1 (en) | 2020-05-19 | 2023-07-13 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
US20210378969A1 (en) | 2020-06-02 | 2021-12-09 | Small Pharma Ltd. | Therapeutic solid dosage forms |
WO2021116503A2 (en) * | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
ES2928395T3 (es) * | 2020-06-02 | 2022-11-17 | Small Pharma Ltd | Composiciones terapéuticas que comprenden compuestos de N,N-dimetiltriptamina deuteratados o parcialmente deuteratados |
KR20230024378A (ko) | 2020-06-12 | 2023-02-20 | 벡클리 싸이테크 리미티드 | 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물 |
US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
EP4122916A1 (en) * | 2021-07-22 | 2023-01-25 | GH Research Ireland Limited | Method for preparing an organic compound |
WO2023002005A1 (en) * | 2021-07-22 | 2023-01-26 | GH Research Ireland Limited | Method for preparing a tryptamine derivative. |
US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
EP4159192A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
WO2023089132A1 (en) | 2021-11-18 | 2023-05-25 | Small Pharma Ltd | Injectable and inhalable formulations |
WO2023108174A1 (en) * | 2021-12-10 | 2023-06-15 | Terran Biosciences, Inc. | Analogs of 6-methoxy- n, n-dimethyltryptamine |
WO2023147423A1 (en) * | 2022-01-28 | 2023-08-03 | Miralogx Llc | Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders |
GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
US20240101514A1 (en) * | 2022-08-19 | 2024-03-28 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
WO2024079314A1 (en) | 2022-10-13 | 2024-04-18 | Cybin Uk Ltd | Method of administration of a parenteral formulation comprising a psychedelic agent |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4336378A (en) | 1980-04-10 | 1982-06-22 | Sandoz, Inc. | Isoxazolyl indolamines |
JPH06508354A (ja) * | 1991-06-21 | 1994-09-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | トリプタミン類似体、その合成法およびその5−ht↓1様または5−ht↓2受容体作用物質としての使用 |
US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
EP1292282A2 (en) | 2000-06-16 | 2003-03-19 | RTP Pharma Inc. | Improved injectable dispersions of propofol |
WO2004085392A1 (en) | 2003-03-25 | 2004-10-07 | Faust Pharmaceuticals | Melatonin derivatives and their use for treating neurological dysfunctions |
US20080103189A1 (en) | 2006-10-19 | 2008-05-01 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted indoles |
WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
CZ302424B6 (cs) * | 2007-06-13 | 2011-05-11 | Zentiva, A. S. | Zpusob prípravy almotriptanu o vysoké cistote |
RU2491067C2 (ru) * | 2007-08-06 | 2013-08-27 | Байотай Терапис, Инк | Способы лечения зависимости |
US20090076121A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched sumatriptan |
EP2209380A4 (en) | 2007-10-09 | 2011-09-14 | Mark T Hamann | METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF |
DK3345902T3 (da) * | 2013-03-14 | 2019-12-09 | Dart Neuroscience Cayman Ltd | Substituerede pyridin- og pyrazinforbindelser som pde4-inhibitorer |
WO2016181414A1 (en) * | 2015-05-12 | 2016-11-17 | Council Of Scientific & Industrial Research | Process for the synthesis of ivacaftor and related compounds |
US20200030309A1 (en) * | 2016-09-29 | 2020-01-30 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
US10933073B2 (en) | 2017-02-09 | 2021-03-02 | Caamtech Llc | Compositions and methods comprising a psilocybin derivative |
WO2018195455A1 (en) | 2017-04-20 | 2018-10-25 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
US11723894B2 (en) * | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
US11117870B2 (en) | 2017-11-01 | 2021-09-14 | Drexel University | Compounds, compositions, and methods for treating diseases |
EP4353314A2 (en) | 2019-02-22 | 2024-04-17 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression |
BR112021016169A2 (pt) | 2019-02-22 | 2021-11-03 | Gh Res Ireland Limited | Composições compreendendo 5-metóxi-n,n-dimetiltriptamina (5-meo-dmt) para uso no tratamento de transtornos mentais |
SG11202109111VA (en) | 2019-02-27 | 2021-09-29 | Univ California | Azepino-indoles and other heterocycles for treating brain disorders |
WO2020176597A1 (en) * | 2019-02-27 | 2020-09-03 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
PL3844147T3 (pl) | 2019-11-07 | 2022-07-18 | Small Pharma Ltd | Związki chemiczne |
CN111072492A (zh) * | 2019-11-29 | 2020-04-28 | 浙江工业大学 | 一种合成3,4-二氯-2-氨基-5-氟联苯的方法 |
CA3166936A1 (en) | 2020-02-04 | 2021-08-12 | Abdelmalik Slassi | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
US20230219889A1 (en) | 2020-05-19 | 2023-07-13 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
WO2021116503A2 (en) | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
US20210378969A1 (en) | 2020-06-02 | 2021-12-09 | Small Pharma Ltd. | Therapeutic solid dosage forms |
GB202008961D0 (en) | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
US20220040150A1 (en) | 2020-08-05 | 2022-02-10 | Universitatsspital Basel | Intravenous dmt administration method for dmt-assisted psychotherapy |
US20220062237A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
MX2022014128A (es) | 2020-08-28 | 2023-02-14 | Small Pharma Ltd | Formulacion inyectable. |
US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
KR20230079351A (ko) | 2020-10-02 | 2023-06-07 | 사이빈 아이알엘 리미티드 | 흡입에 의한 심리치료제(psychedelic) 약물의 전달을 위한 방법 및 이 방법을 수행하기 위한 시스템 |
US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2020
- 2020-11-09 PL PL20816376.6T patent/PL3844147T3/pl unknown
- 2020-11-09 HU HUE20816375A patent/HUE061482T2/hu unknown
- 2020-11-09 HR HRP20230281TT patent/HRP20230281T1/hr unknown
- 2020-11-09 HU HUE20816376A patent/HUE059403T2/hu unknown
- 2020-11-09 ES ES20816375T patent/ES2940811T3/es active Active
- 2020-11-09 JP JP2022526073A patent/JP7422473B2/ja active Active
- 2020-11-09 EP EP20816375.8A patent/EP3873883B1/en active Active
- 2020-11-09 WO PCT/EP2020/081502 patent/WO2021089872A1/en active Application Filing
- 2020-11-09 AU AU2020378647A patent/AU2020378647B2/en active Active
- 2020-11-09 NZ NZ788543A patent/NZ788543A/en unknown
- 2020-11-09 AU AU2020381103A patent/AU2020381103B2/en active Active
- 2020-11-09 KR KR1020237033500A patent/KR20230142817A/ko not_active Application Discontinuation
- 2020-11-09 PT PT208163758T patent/PT3873883T/pt unknown
- 2020-11-09 HR HRP20220797TT patent/HRP20220797T1/hr unknown
- 2020-11-09 CN CN202080087092.5A patent/CN114829341B/zh active Active
- 2020-11-09 DK DK20816376.6T patent/DK3844147T3/da active
- 2020-11-09 EP EP20816376.6A patent/EP3844147B1/en active Active
- 2020-11-09 WO PCT/EP2020/081503 patent/WO2021089873A1/en unknown
- 2020-11-09 BR BR112022008919A patent/BR112022008919A2/pt not_active Application Discontinuation
- 2020-11-09 KR KR1020227018623A patent/KR20220082092A/ko not_active IP Right Cessation
- 2020-11-09 CN CN202080087091.0A patent/CN114829340B/zh active Active
- 2020-11-09 MX MX2022005399A patent/MX2022005399A/es unknown
- 2020-11-09 ES ES20816376T patent/ES2920681T3/es active Active
- 2020-11-09 CA CA3160334A patent/CA3160334C/en active Active
- 2020-11-09 IL IL292753A patent/IL292753B2/en unknown
- 2020-11-09 JP JP2022526074A patent/JP7423131B2/ja active Active
- 2020-11-09 PL PL20816375.8T patent/PL3873883T3/pl unknown
- 2020-11-09 EP EP22214748.0A patent/EP4180037A1/en active Pending
- 2020-11-09 CA CA3160337A patent/CA3160337C/en active Active
- 2020-11-09 PT PT208163766T patent/PT3844147T/pt unknown
-
2021
- 2021-08-26 US US17/412,828 patent/US11643390B2/en active Active
-
2022
- 2022-05-03 IL IL292754A patent/IL292754A/en unknown
- 2022-05-06 US US17/662,261 patent/US11578039B2/en active Active
-
2023
- 2023-01-10 US US18/152,465 patent/US20230167056A1/en active Pending
- 2023-03-31 US US18/193,866 patent/US20230250059A1/en active Pending
- 2023-11-30 JP JP2023202672A patent/JP2024028798A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL292753A (en) | compounds | |
IL289463A (en) | Agonist-gipr compounds | |
GB201905721D0 (en) | Compounds | |
GB201916915D0 (en) | Compounds | |
GB201910305D0 (en) | Compounds | |
GB201908536D0 (en) | Compounds | |
GB201908171D0 (en) | Compounds | |
GB201910304D0 (en) | Compounds | |
GB201908095D0 (en) | Carboxy-MIDA-boronate compounds | |
GB201919205D0 (en) | Compounds | |
GB201918761D0 (en) | Compounds | |
GB201918424D0 (en) | Compounds | |
GB201917895D0 (en) | Compounds | |
GB201917893D0 (en) | Compounds | |
GB201917891D0 (en) | Compounds | |
GB201916847D0 (en) | Compounds | |
GB201916572D0 (en) | Compounds | |
GB201916597D0 (en) | Compounds | |
GB201916595D0 (en) | Compounds | |
GB201916142D0 (en) | Compounds | |
GB201914208D0 (en) | Compounds | |
GB201913633D0 (en) | Compounds | |
GB201913541D0 (en) | Compounds | |
GB201912850D0 (en) | Compounds | |
GB201911848D0 (en) | Compounds |